This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests John McCamant, editor The Medical Technology Stock Letter.
Incyte (INCY) is poised for a strong performance in 2017 that will be driven by three major catalysts.
The first is that the firm’s drug Jakafi will continue to be a compelling and sustainable high margin long-term growth driver for myeloproliferative disorders myelofibrosis (MF) and polycythemia vera (PV).
The recent failure from a competitor’s Phase III studies of momelotinib has removed a major uncertainty on the revenue front for INCY’s key commercial product. The potential upside of Jakafi sales in both MF and PV represents a significant growth opportunity.
Partner Eli Lilly (LLY) will sell INCY’s baricitinib in rheumatoid arthritis and we expect a strong commercial launch that will be driven by the potential to be another “Best in Class” drug.